Pharmacological and toxicological evaluations of the new pyrazole compound (LQFM-021) as potential analgesic and anti-inflammatory agents.
Chronic inflammation is a world health problem. There is a need to develop new anti-inflammatory and analgesic drugs with improved activity and reduced side effects. In this context, the aim of this study was to evaluate the antinociceptive and anti-inflammatory effects of the pyrazole compound LQFM-021 after acute and sub-chronic administration in rats submitted to a CFA-induced chronic arthritis model, as well as compare the toxicity of this compound to that of dipyrone, given throughout 7 days. Firstly, we observed that acute oral administration of the higher dose (130 µmol/kg) of LQFM-021 reduced paw lifting time (PET) and edema formation. These effects disappeared on the following day, requiring another dose to maintain the effects. This dose also promoted reduction of the polymorphonuclear recruitment in the synovial fluid. In another experiment, both treatments with LQFM-021, 65 µmol/kg twice a day and 130 µmol/kg once a day, produced a progressive and permanent reduction of the PET and edema, also reducing polymorphonuclear recruitment. However, the single treatment with 130 µmol/kg was more effective than the double treatment with 65 µmol/kg. LQFM-021 did not produce toxicity signs. However, dipyrone (130 µmol/kg once a day) promoted erosion of the epithelial cells and decreased mucus in the gastric mucosa. These data indicate that LQFM-021 produced antinociceptive and anti-inflammatory effects in CFA-induced arthritis in rats. These effects occurred in the absence of apparent toxic effects, indicating that the pyrazole compound LQFM-021 may be considered a good prototype for development of new analgesic/anti-inflammatory drug.
Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil. iziara_bia@hotmail.com.
Iziara F
IF
Florentino
Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Daiany P B
DP
da Silva
Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
José Luís R
JL
Martins
Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Taciane S
TS
da Silva
Department of Histology, Embryology and Cell Biology, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Fernanda C A
FC
Santos
Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Carlos R
CR
Tonussi
Chemistry Institute, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Géssica A
GA
Vasconcelos
Chemistry Institute, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Boniek G
BG
Vaz
Chemistry Institute, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Luciano M
LM
Lião
Laboratory of Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Federal University of Goiás, Goiânia, GO, Brazil.
Ricardo
R
Menegatti
Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Campus Samambaia, Goiânia, GO, Brazil.
Elson A
EA
Costa
D000700:Analgesics / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use* / Q000633:toxicity; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology; D011720:Pyrazoles / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles / Q000627:therapeutic use* / Q000633:toxicity
C585652:5-(1-(3-fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013777:Tetrazoles
Anti-inflammatory; Arthritis; Dipyrone; Gastric mucosa; LQFM-021; Pyrazole compound
Gastroenterology. 2004 Jul;127(1):145-54
15236181
Eur J Pharmacol. 1994 Jan 14;251(2-3):173-9
7908638
FEBS Lett. 2013 Dec 11;587(24):3898-905
24188822
Am J Physiol. 1993 Sep;265(3 Pt 1):G418-22
8214062
Life Sci. 2014 Jan 30;95(2):81-8
24355293
Eur J Med Chem. 2008 Jun;43(6):1237-47
17889969
Drug Dev Res. 2016 Feb;77(1):20-8
26763139
Eur J Pharmacol. 2009 Aug 15;616(1-3):91-100
19540223
Int J Exp Pathol. 2015 Jun;96(3):188-95
26098999
Bioorg Med Chem. 2015 Jul 1;23(13):3059-80
26014481
Nitric Oxide. 2015 May 1;47:17-24
25754796
J Glob Health. 2015 Jun;5(1):010409
25969732
Physiol Rev. 1999 Oct;79(4):1193-226
10508233
Chem Pharm Bull (Tokyo). 2013;61(5):524-31
23649195
Eur J Pain. 2006 Aug;10(6):537-49
16199187
Physiol Rev. 2008 Oct;88(4):1547-65
18923189
Dig Dis Sci. 2002 Dec;47(12):2791-8
12498303
Biochem Pharmacol. 2015 Dec 15;98 (4):564-72
26394025
Cytokine. 2006 Oct;36(1-2):83-9
17166735
Skeletal Radiol. 2006 Mar;35(3):156-64
16249900
Pharmacol Biochem Behav. 2015 Feb;129:72-8
25511393
Int Immunopharmacol. 2016 Mar;32:16-23
26780232
Lab Invest. 1963 Feb;12:131-55
13999512
Bioorg Med Chem. 2012 May 15;20(10):3306-16
22516672
Life Sci. 2008 Nov 21;83(21-22):739-46
18848839
Braz J Med Biol Res. 2006 Jun;39(6):795-9
16751986
J Physiol Pharmacol. 2002 Mar;53(1):39-50
11939718
J Ethnopharmacol. 2003 Sep;88(1):15-8
12902047
Bioorg Chem. 2015 Feb;58:104-16
25590381
Eur J Med Chem. 2016 Feb 15;109 :216-37
26774927
Eur J Pharmacol. 1999 Jan 22;365(2-3):259-66
9988110
BMJ. 1996 Jun 22;312(7046):1563-6
8664664
J Clin Gastroenterol. 1981;3(Suppl 2):45-50
7320468
Inflammation. 1994 Aug;18(4):399-405
7982729